Amphista Therapeutics

A new approach to protein degradation

Amphista Therapeutics is using a novel mechanism of targeted protein degradation (TPD) to hijack the cell’s degradation machinery to modulate the abundance of proteins that are responsible for disease progression.

Powered by transformational science, they are advancing beyond traditional degrader approaches using their proprietary Eclipsys™ Drug Development Platform. Amphista’s approach to protein degradation differentiates from traditional TPD technologies by expanding the scope for therapeutic applications and reducing the risk of resistance in oncology indications.

CEO  Nicola Thompson

Advent Contact  Dominic Schmidt

Advent founded and seeded Amphista in 2018.
Private Companies
12 September 2022 in Amphista Therapeutics, Press Release, Private Companies

Fierce Biotech Names Amphista Therapeutics as One of its “Fierce 15” Biotech Companies of 2022

Press Release.   Cambridge, UK – September, 12, 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it…
Read More
4 May 2022 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics

Press Release.   Amphista and Merck will collaborate to leverage Amphista’s proprietary EclipsysTM TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes  up to €39…
Read More
4 May 2022 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics

Press Release.   Amphista and Bristol Myers Squibb to collaborate and leverage Amphista’s proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics Collaboration includes an upfront payment…
Read More
6 December 2021 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics Appoints Dr Martin Pass as CDO

Press Release.   Amphista Therapeutics Appoints Dr Martin Pass as CDO Cambridge, England, 6 December 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today…
Read More